{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Files DC"],"funding":["NHLBI NIH HHS"],"pagination":["100168"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12823136"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["3(3)"],"pubmed_abstract":["<h4>Background</h4>A phase 2 trial of high-dose IV ascorbate suggested reduced mortality in patients with ARDS, although trials in sepsis have failed to show clinical benefit.<h4>Research question</h4>Does IV high-dose ascorbate improve outcomes in patients with sepsis at risk of or with ARDS?<h4>Study design and methods</h4>In this phase 2b multicenter randomized placebo-controlled trial, patients with known or suspected infection and either shock or acute hypoxemic respiratory failure were randomized to ascorbate (50 mg/kg IV every 6 hours for 5 days) or a matching placebo. The primary outcome was days alive and free of respiratory, renal, and circulatory organ support to day 28. Secondary outcomes included clinical and biological end points.<h4>Results</h4>After enrolling 79 participant"],"journal":["CHEST critical care"],"pubmed_title":["Ascorbate for Organ Dysfunction in Critically Ill Patients With Sepsis: The Phase 2b ASTER Trial."],"pmcid":["PMC12823136"],"funding_grant_id":["U01 HL122998","U01 HL122989","U01 HL123008","U01 HL123009","U01 HL123018","U01 HL123004","U01 HL123027","U01 HL123022","U01 HL123033","U01 HL123023","U01 HL123020","U01 HL123031","U01 HL123010"],"pubmed_authors":["Hendey GW","Ginde A","Chang SY","Aggarwal NR","Gibbs KW","Tidswell MA","Moskowitz A","Goodwin A","Robinson BRH","Fowler AA","Brown SM","Miller C","Self WH","Ware LB","Brower RG","Khan A","Yealy DM","Hibbert K","Liu KD","Riker R","Thompson BT","Matthay MA","Hough CL","Huang W","Fields S","Harris ES","Files DC","Duggal A","Lai P","Douglas IS","Hite RD","Foulkes AS"],"additional_accession":[]},"is_claimable":false,"name":"Ascorbate for Organ Dysfunction in Critically Ill Patients With Sepsis: The Phase 2b ASTER Trial.","description":"<h4>Background</h4>A phase 2 trial of high-dose IV ascorbate suggested reduced mortality in patients with ARDS, although trials in sepsis have failed to show clinical benefit.<h4>Research question</h4>Does IV high-dose ascorbate improve outcomes in patients with sepsis at risk of or with ARDS?<h4>Study design and methods</h4>In this phase 2b multicenter randomized placebo-controlled trial, patients with known or suspected infection and either shock or acute hypoxemic respiratory failure were randomized to ascorbate (50 mg/kg IV every 6 hours for 5 days) or a matching placebo. The primary outcome was days alive and free of respiratory, renal, and circulatory organ support to day 28. Secondary outcomes included clinical and biological end points.<h4>Results</h4>After enrolling 79 participant","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-06T22:05:10.222Z","creation":"2026-06-05T03:12:20.124Z"},"accession":"S-EPMC12823136","cross_references":{"pubmed":["41574117"],"doi":["10.1016/j.chstcc.2025.100168"]}}